Carboxyamidotriazole Orotate is under clinical development by Tactical Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Carboxyamidotriazole Orotate’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 28 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Carboxyamidotriazole Orotate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Carboxyamidotriazole Orotate overview

Carboxyamidotriazole orotate (CTO) is under development for the treatment of non-small cell lung cancer, head and neck cancer, metastatic colorectal cancer, glioblastoma multiforme, malignant glioma, prostate cancer and metastatic melanoma. It is administered orally. The drug candidate targets calcium-channel-mediated calcium influx. It was also under development for the treatment of age-related macular degeneration

It was under development for ovarian cancer, metastatic colorectal cancer, synovial sarcoma, renal Cell Carcinoma, synovial Sarcoma, leiomyosarcoma, squamous Non-Small Cell Lung Carcinoma, colon Carcinoma.

Tactical Therapeutics overview

Tactical Therapeutics operates in pharmaceutical and healthcare industry. It is headquartered in United States.

Quick View Carboxyamidotriazole Orotate LOA Data

Report Segments
  • Innovator
Drug Name
  • Carboxyamidotriazole Orotate
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.